Krop Julie

SEC Form 4 insider trading activity

Krop Julie has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Jun 24, 2026.

On the most recent filing, Krop Julie is listed as Director at Aquestive Therapeutics, Inc. Inside the rolling window, Krop Julie reported no open-market purchases and 1 open-market sale totaling $125K in AQST.

Companies traded

Other insiders at AQST

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$125K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
AQST
Krop Julie
Sale$125KJun 24SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Krop Julie made?

Krop Julie has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company since 2026.

Which companies does Krop Julie trade?

Krop Julie has filed SEC Form 4 disclosures for 1 company, including AQST.

When was Krop Julie's most recent SEC Form 4 filing?

Krop Julie's most recent SEC Form 4 filing on Tracefour is dated Jun 24, 2026.

What is Krop Julie's total buy and sell value in the current window?

Inside the rolling retention window, Krop Julie bought $0 and sold $125K based on SEC Form 4 filings.

What was Krop Julie's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 25,000 AQST shares on 2026-06-23, worth $125K, per SEC Form 4 filings.